Prevention of diseases

The Food, Dmg and Cosmetics Act defines a cosmetic as a substance intended to be mbbed, poured, sprinkled, or sprayed on, introduced into, or otherwise appHed to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance. A dmg is defined as an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or other animals, and articles intended to affect the stmcture or any function of the body of humans or other animals. 

Epidemiology operates within the context of public health with a strong emphasis on the prevention of disease through the reduction of factors that may increase the likelihood that an individual or group will suffer a given disease. Implicit in the practice of epidemiology is the need for different disciplines in studying the influence of occupation on human health. 

Educating the Patient and Family Because of the effectiveness of various types of vaccines in the prevention of disease, nurses must inform the public about the advantages of immunization. Barents are encouraged to have infants and young children receive the immunizations suggested by the primary health care provider. 

Intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. 

To assess for prevention of disease progression, practitioners may utilize serial echocardiograms every 6 months to assess cardiac function and evaluate the effects of drug therapy. 

Prevention of disease complications (e.g., dermatologic infections and skin breakdown, delay institutionalization) Avoidance or minimization of adverse consequences of treatment... 

I. ROLE OF DRUGS AND DRUG PRODUCTS IN THE TREATMENT AND PREVENTION OF DISEASE... 

FDCA defines drugs as articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and articles (other than food) intended to affect the structure or any function of the body. Therefore, a product becomes a drug based upon its intended use and not upon its composition or source [26]. A pharmacist may violate the FDCA if he or she recommends and sells a dietary supplement for the treatment of a particular disease—the pharmacist would be indicating the product as an unapproved drug. However, if the pharmacist is not selling the product, the FDCA would not be violated. 

In summary, the amazing breadth and depth of research in carotenoids are reasons why it draws investigators are drawn to this fascinating field of research. The research spans the continuum, from detailed studies of the roles of photoprotective carotenoids in plants to the potential application in the prevention of disease in humans. This is translational research at its best and I commend the editor, Dr. John Landrum, for assembling such an interesting and informative collection of current research. 

Prevention of diseases Disinfected, insect netting Rotation, resistance... 

Prevention of disease through appropriate livestock husbandry (including feeding regimes) (see also Chapter 10)... 

High-throughput proteomic methods hold great promise for the discovery of novel protein biomarkers that can be translated into practical interventions for the diagnosis, treatment, and prevention of disease. These approaches may also facilitate the development of therapeutic agents that are targeted to specific molecular alterations in diseases such as cancer. In many cases, malignant cells yield unique protein profiles when total protein extracts from such cells are analyzed by 2-D gel electrophoresis or mass spectrometry (MS) methods. Such proteomic studies have the potential to provide an important complement to the analysis of DNA and mRNA extracts from these tissues.1... 

In those patients who did not receive the influenza vaccination and are receiving an antiviral drug for prevention of disease during the influenza season, the medication should optimally be taken for the entire duration of influenza activity in the community. 

Direct costs include both medical and nonmedical expenditures for the detection, treatment, and prevention of disease. Direct medical costs reflect resources consumed in the "production" of health care, such as pharmaceutical products and services, physician visits, and hospital care. Direct nonmedical costs reflect expenditures for products and services that are not directly related to disease treatment but are still related to patient care. Examples of direct nonmedical costs include transportation to a pharmacy or physician s office and housekeeping during the illness period. Indirect costs account for changes in productivity of an individual because of illness. The monetary value of lost or altered productivity is typically used as a measure of indirect costs. Intangible costs and consequences are nonmonetary in nature and reflect the impact of disease and its treatment on the individual s social and emotional functioning and quality of life. Table 12.2 provides examples of these types of costs and consequences. 

Prevention of disease is of course very important and the individual have a responsibility for their own health in a short and long perspective. The health care system has to support the individual to make correct decision and also to further help them when disease is evident. The cornerstone to this is surgery and medication treatment. As described in Chapter 3 there are requirements for documentation of new medications when used in the elderly. However those controlled trials will always be artificial and we need more evidences and comparisons from normal clinical use based on populations and individuals. This information could be gathered continuously if the patient care supportive IT system really was supportive. 

Nutritional supplements are consumed for prevention of diseases and maintenance of a state of wellbeing. 

The great strides made toward the application of liposomes in the treatment and prevention of disease over nearly four decades are largely due to developments in liposome technology earlier achievements were included in the previous two editions of this book (7,8). The avalanche of new techniques that came with further expansion of liposomology since... 

Fundamental healthcare issues may also be involved in the situation of policy-driven therapeutic research. The future investment of society in health may require a large-scale national clinical trial to answer questions relating to the prevention of disease or premature death. This type of clinical trial will not simply relate to one manufacturer s product. As such, it is preferable that the trial is organised on a national level, not necessarily with the exclusion of the company(s) involved. An independent data-monitoring committee (IDMC) should oversee the clinical trial with as much support from the pharmaceutical company(s) as possible. The clinical data collected belongs to the state and should be treated with the same quality standards as any pharmaceutical company sponsored study. 

---